Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.78 -0.08 (-0.58%)
Official Closing Price Updated: 4:10 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 984,229
Open 13.76
Bid (Size) 13.60 (2)
Ask (Size) 14.11 (1)
Prev. Close 13.86
Today's Range 13.72 - 13.86
52wk Range 12.57 - 15.08
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — 
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
From Takeda Pharmaceutical Company Limited
Via Business Wire

Performance

YTD
-3.91%
-3.91%
1 Month
-3.64%
-3.64%
3 Month
-0.65%
-0.65%
6 Month
+3.07%
+3.07%
1 Year
+0.07%
+0.07%

More News

Read More
Preview: Takeda Pharmaceutical's Earnings
Via Benzinga
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
From Takeda Pharmaceutical Company Limited
Via Business Wire
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
Via Benzinga
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Via Benzinga
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
Via MarketBeat
Topics Economy
Exposures Interest Rates
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Via Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
Via Benzinga
Exposures Product Safety
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
Via Benzinga
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
Via InvestorPlace
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
From Takeda Pharmaceutical Company Limited
Via Business Wire
3 Biotech Stocks to Buy on the Dip: July 2024
Via InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Via Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Via Benzinga
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
Via Talk Markets
Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.